Aducanumab has its approval — now, let citizen-scientists come together to see if it works
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.
Editor’s Note: Madhav Thambisetty was an advisor on the FDA’s Peripheral and Central Nervous System Drugs advisory committee that voted overwhelmingly not to recommend Alzheimer’s drug aducanumab’s approval by the FDA. Thambisetty’s views in this op-ed are not reflections of the positions of the FDA or the NIH’s National Institute on Aging, where he is a section chief of the clinical and translational neuroscience section in the laboratory of behavioral neuroscience.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.